Archive for October, 2008

JCNN News Summaries - Japan Corporate News Network - Daiichi Products Covered by National Health Insurance

Monday, October 27th, 2008

Tokyo, Apr 5, 2006 - (JCN) - Some of Daiichi Pharmaceutical’s Intrathecal Baclofen therapy products are now listed for national health insurance reimbursement. One of them is the SynchroMed infusion system that comprises of the SynchroMed EL pump and the InDura catheter.
Intrathecal Gabalon (baclofen) and the SynchroMed system are used to treat severe spasticity in patients if conventional treatments don’t. The system i…

Internal Medicine News - Baclofen Reduces Symptoms of Duodenogastroesophageal Reflux.

Tuesday, October 21st, 2008

ATLANTA — Baclofen inhibits transient lower esophageal sphincter relaxations associated with duodenogastroesophageal reflux, Dr. Geert Koek said at the annual Digestive Disease Week.
According to Dr. Geert Koek of Catholic University, Leuven, Belgium, duodenogastroesophageal reflux disease is differentiated from gastroesophageal reflux disease by significant amounts of refluxed bile from the duodenum. Patients can have persist…

Business Wire - Lannett Receives Approval to Market Baclofen 10mg Tablets

Thursday, October 16th, 2008

New Dosage Expands Sales Reach
PHILADELPHIA — Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Baclofen 10mg tablets, bolstering the company’s existing product offering of Baclofen 20mg tablets.
Total U.S. annual sales as of May 2007 for Baclofen 10mg were $153 million and $108 million for Baclofen 20mg, accordin…

Bandolier - Intrathecal baclofen for severe spasticity

Sunday, October 12th, 2008

Health service purchasers are often faced with the problem of making decisions in the absence of evidence on benefit and cost. Evidence is most often lacking in rare but severe conditions, and in early applications of new technology. The example of intrathecal baclofen for severe spasticity [1] shows that even in these difficult circumstances sufficient evidence may be garnered…

Journal of Neuroscience Nursing - Intrathecal baclofen therapy over 10 years.

Saturday, October 11th, 2008

Abstract: Intrathecal baclofen (ITB) therapy has evolved into a standard treatment for severe spasticity. After this therapy had been provided for 10 years, a retrospective chart review on 50 patients, representing a total 2,922 patient months of ITB service, was done. These patients suffered severe spasticity from a number of disease processes including mul…

Internal Medicine News - Intrathecal Baclofen Reduces Spasticity in Stroke. (Patients Able to Walk, Climb Stairs).(Brief Article)

Thursday, October 9th, 2008

SAN DIEGO - Intrathecal infusions of baclofen reduce lower limb spasticity and improve function in stroke survivors, even years after the initial stroke, Dr. Gerard Francisco reported at a meeting sponsored by the National Stroke Associ…

Paraplegia News - Medication alert: Baclofen shortage? (Veterans Benefits).

Monday, October 6th, 2008

Baclofen is manufactured in the United States, but its raw ingredients come from several countries. The primary manufacturer has been unable to obtain an adequate supply of the drug since late last summer, and there is now a shortage of the oral (pill) form.
Other pharmaceutical companies are receiving some of the raw product and continue to make Baclofen pills. They …